SARS-CoV-2 NSP16 Targeted Library

Summary of the technology

SARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library, which contains 1049 compounds with predicted activity against SARS-CoV-2 NSP16 is offered. The library has been designed with receptor-based virtual screening using crystal structure of SARS-CoV-2 2′-O-MTase (PDB ID: 6WKQ).

Otava Research Institute

Details of the Technology Offer

2′-O-methyltransferase (2′-O-MTase, non-structural protein 16, nsp16) can act as potential drug target for the SARS-CoV-2. It prevents recognition and activation of the host immune response which is essential for successful viral infection. OTAVAchemicals offers SARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library (1049 compounds with predicted activity against SARS-CoV-2 NSP16). The library has been designed with receptor-based virtual screening using crystal structure of SARS-CoV-2 2′-O-MTase (PDB ID: 6WKQ). The overall procedure included accurate flexible docking of Drug-like Green Collection into methyltransferase catalytic site. Final selection of compounds was made with inspection of enzyme active site’s crucial structural determinants for ligand binding, docking scores and intermolecular hydrogen bonds with key active site’s amino acid residues.

Related Keywords

  • Applications for Health
  • Biological Sciences
  • Medicine, Human Health
  • Biostatistics, Epidemiology
  • Virus, Virology / Antibiotics / Bacteriology
  • Biology / Biotechnology
  • Infectious Diseases
  • Medical/health
  • Medical Health related
  • Diagnostic
  • Diagnostic services
  • Other Medical/Health Related
  • Covid-19
  • compounds
  • coronavirus
  • sars-cov-2

About Otava Research Institute

Otava Institute is a global provider of one-stop integrated research solutions for business and life science. Our team includes chemists, biologists, physicists whose combined efforts contribute to the complex contract research projects for pharmaceutical, agro, cosmetic and material science industries.We are dedicated to providing clients with outstanding service in these key areas and will continue to push boundaries to remain an industry front-runner. Each day we expand our core competencies delivering of new technologies to meet all the customer’s needs.

Our location in Toronto Ontario, Canada provides our clients with the added advantage of North American IP rules and regulations and secure communication and logistics. Our Ukraine – based R&D facilities represented with the Ukrainian Laboratories, that is cooperating with leading Ukrainian research institutions and carries out research work in the format of outsourcing.

We work as a preferred partner to many of the world’s top 10 pharma firms, and hundreds of other companies, providing support with creative solutions for complex technical compound issues. Our scientific knowledge, combined with our research and manufacturing capability, enables us to support chemical processing and production without ever compromising on quality.

Our experience, dedication, and commitment to quality make us an ideal partner for discovery stage research.

Taras Maiula

Never miss an update from Taras Maiula

Create your free account to connect with Taras Maiula and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Taras

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support